Dopavision

At Dopavision, our mission is to bring a new perspective to the world of eye care by developing an innovative and widely accessible myopia intervention. By addressing a massive global public health problem, we aim to empower as many people as possible to build a healthier, brighter future. MyopiaX is our transformative approach designed to slow the progression of myopia (nearsightedness) in children and adolescents. By combining selective ocular light stimulation with easily accessible consumer electronics, MyopiaX non-invasively engages the eye’s innate growth regulation mechanism. Created for everyday life, MyopiaX seeks to provide an interactive and intuitive child-friendly alternative to control myopia. MyopiaX is being investigated in a multicentre, randomized, controlled clinical trial evaluating the safety, tolerability, and signals of clinical effect of MyopiaX on the progression of myopia in children (NCT04967287). The MyopiaX-1 clinical trial achieved its 6-month milestone in April 2024 and is scheduled to conclude in September 2024. Founded in 2017, Dopavision GmbH has raised €16.2 million in private equity and public grants, and is backed by top-tier international investors including Seventure Partners, Novartis Pharma (dRx Capital), Boehringer Ingelheim Venture Fund, and Ababax Health. Our efforts are further supported by the German Federal Ministry of Education and Research (BMBF) via the “Industrie-in-Klinik” program.